ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor
WALTHAM, Mass. -- November 05, 2012
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops
anticancer therapeutics using its antibody expertise and Targeted Antibody
Payload (TAP) technology, today announced that the following presentations by
Company management at upcoming investor conferences will be webcast:
*Lazard Capital Markets 9^th Annual Healthcare Conference
3:00 pm ET on November 14, 2012 in New York, NY
Presenter: Gregory Perry, Executive Vice President and CFO
*Jefferies 2012 Global Healthcare Conference in London
10:00 am GMT (5:00 am ET) on November 15, 2012 in London, England
Presenter: Daniel Junius, President and CEO
A webcast of each presentation can be accessed live through the “Investor
Information” section of the Company’s website, www.immunogen.com; a replay of
each presentation will be available at the same location for one week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's
expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing
agents and engineered linkers. The Company's TAP technology uses monoclonal
antibodies to deliver one of ImmunoGen's proprietary cancer-killing agents
specifically to tumor cells. There are now ten TAP compounds in clinical
development, of which three are wholly owned by the Company. ImmunoGen’s
collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly,
Novartis, Roche, and Sanofi. Marketing applications for trastuzumab emtansine
(T-DM1), the most advanced compound using ImmunoGen’s TAP technology, have
been submitted in the US and Europe. Roche is developing this compound under
an agreement between ImmunoGen and Genentech, a member of the Roche Group.
More information about ImmunoGen can be found at www.immunogen.com.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
Press spacebar to pause and continue. Press esc to stop.